Repositioning Candidate Details
| Candidate ID: | R0446 |
| Source ID: | DB06311 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Darapladib |
| Synonyms: | |
| Molecular Formula: | C36H38F4N4O2S |
| SMILES: | CCN(CC)CCN(CC1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)C(=O)CN1C2=C(CCC2)C(=O)N=C1SCC1=CC=C(F)C=C1 |
| Structure: |
|
| DrugBank Description: | |
| CAS Number: | 356057-34-6 |
| Molecular Weight: | 666.78 |
| DrugBank Indication: | Investigated for use/treatment in atherosclerosis. |
| DrugBank Pharmacology: | |
| DrugBank MoA: | Darapladib is a selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2 is an enzymatic upstream mediator of inflammatory processes. Evidence from experimental settings show that the breakdown products from oxidized low density lipoprotein C (LDL-C)such as lysophosphatidylcholine species and oxidized nonesterified fatty acids are pro-inflammatory and pro-apoptotic. These products are suspected to cause athlerosclerosis progression and plaque vulnerability, which leads to increased risk of cardiovascular problems. |
| Targets: | Cytosolic phospholipase A2 |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|